NCT06821048View on ClinicalTrials.gov

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

December 1, 2027

Conditions
Colorectal CancerStomach CancerPancreatic CancerMetastatic Cancer
Interventions
BIOLOGICAL

Intraperitoneal infusion of FAST CEA-targeted CAR-T

Intraperitoneal infusion of FAST CEA-targeted CAR-T (PTC13); Subjects will be treated with Fludarabine and Cyclophosphamide based lymphodepleting chemotherapy before CAR-T cell infusion.

Trial Locations (1)

310006

RECRUITING

the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou

All Listed Sponsors
collaborator

Chongqing Precision Biotech Co., Ltd

INDUSTRY

lead

Weijia Fang, MD

OTHER